Spartan Bioscience Inc., a Canadian molecular diagnostics company that develops, manufactures, and markets DNA analyzers for on-demand applications, today announced the unveiling of the prototype Spartan DX-12(TM) DNA analyzer. This new addition to the Spartan product line is a direct result of feedback provided by evaluation partners in molecular biology labs across the U.S. and […]

VEDBAEK, Denmark, October 27 — The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971). Results were announced today at the 2008 International Gynecologic Cancer Society (IGCS) biennial meeting in Bangkok, Thailand. In this study, Oncotech EDR […]

SAN DIEGO–Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, announced today that Celera Corporation has extended its license agreement of Nanogen’s patent portfolio in molecular biology to develop additional diagnostic products. Celera Corporation will use Nanogen’s Minor Groove Binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This […]

Customers can improve overall accuracy by combining Promega Maxwell® DNA extraction and One Lambda HLA assays MADISON, Wis.–Promega Corporation, a leading life sciences company, and One Lambda, Inc, a leading producer of transplant diagnostic products, will co-market the Promega Maxwell® 16 DNA extraction system with One Lambda LABType® SSO and Micro SSP™ tests in the […]

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from […]

Expanded and Enhanced Facilities and Services to Meet the Needs of More Patients, Healthcare Providers and Third Party Administrators WALTHAM, Mass., Oct 21, 2008 — PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced that its NTD Laboratories (NTD) subsidiary relocated its headquarters, prenatal screening laboratory, and research and development (R&D) laboratory […]

Leading Syndicate of New and Existing Investors Support Development of Non-Invasive Cancer Diagnostics LEXINGTON, Mass. & SAN DIEGO–Predictive Biosciences, an emerging molecular diagnostics company developing non-invasive diagnostic products for informed cancer management™, today announced the closing of a $21.75 million Series B financing. The financing was led by new investor New Enterprise Associates (NEA), a […]

Excellent standards in production of sepsis test portfolio for clinical routine approved JENA, Germany–SIRS-Lab today announced its Quality Management certification for in-vitro diagnostics. After building up a new production suite, the company now accelerates the further clinical routine implementation of its molecular diagnostic tests for sepsis. The in-vitro diagnostics certification is the official approval for […]

TEMPE, Ariz., Oct. 16 — A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, […]

COPENHAGEN, October 16 — Exiqon today announces the adoption of the name Exiqon Diagnostics for its U.S. subsidiary to signal the company’s commitment to expanding its business to a broad offering in molecular and cellular-based diagnostics that guide treatment decisions in oncology. Exiqon is pleased to announce the adoption of a new name for their […]